Alzheimer’s disease is rewriting the rules of drug discovery, with companies like Eli Lilly and others abandoning caution to keep pursuing an elusive hypothesis because the potential payoff is so great.
With almost all carmakers heaping on the discounts to keep the U.S. auto market at a plateau, Subaru just notched its 63rd straight monthly sales gain, with minimal incentives to get customers in the door.
Dan Coats sought to tamp down tensions between President Donald Trump and U.S. intelligence agencies, assuring former Senate colleagues at his confirmation hearing that he would act independently as director of national intelligence.
Former Indiana Sen. Dan Coats is likely to face tough questioning because President Donald Trump has nominated him to supervise the nation’s 17 intelligence agencies while they’re mired in explosive investigations.
While corn is still king, farmers from North Dakota to Texas are preparing to use more of their land on soybeans instead. And the reason why is obvious.
Cigna Corp. and Anthem Inc. are trading accusations of harassment and sabotage in competing lawsuits as the two health companies feud publicly in the wake of a stalled $48 billion merger.
Indianapolis-based Anthem Inc. on Wednesday won a court ruling blocking Cigna Corp. from terminating a proposed merger between the health insurers until a judge could weigh arguments over the faltering deal at an April 10 hearing.
Merck & Co. on Tuesday announced that it will end a study of its once-promising Alzheimer’s disease drug in patients with mild-to-moderate forms of the condition, just three months after Eli Lilly and Co. announced its own setback in a field that’s been littered with failures.
Indianapolis-based Anthem responded almost immediately Tuesday by saying Cigna does not have the right to cancel the deal.
Federal Reserve Chairwoman Janet Yellen said more interest-rate increases will be appropriate if the U.S. economy meets the central bank’s outlook of gradually rising inflation and tightening labor markets.
The Humana-Aetna deal was one of two mergers that would have reshaped the U.S. health insurance landscape. Both were rejected by federal judges as anticompetitive. Anthem hasn't given up on its deal—a $48 billion pact to acquire Cigna—and is pressing ahead with an appeal.
Anthem filed a notice of appeal on Thursday after a federal judge blocked its $48 billion deal to buy Cigna Corp.
Vice President Mike Pence may have just picked another fight with pharmaceutical companies—one that doesn’t involve drug prices.
The deal, along with Aetna Inc.’s proposed tie-up with Humana Inc., which was blocked last month, was set to reduce the ranks of big U.S. health insurers to three from five and make Anthem the largest by membership.
Companies have spent the last few years beefing up their parental-leave policies to attract and retain the most sought-after workers. Up next in the benefits arms race: helping workers deal with sickness and death.
If a deal occurs, Hudson’s Bay might fold Macy’s assets, worth about $20 billion, into HBS Global Properties, its joint venture with Indianapolis-based Simon Property Group.
Eli Lilly and Co. CEO Dave Ricks said he was encouraged by President Donald Trump’s understanding of the complexities of drug development, yet he’s concerned about risks the industry may face in a fresh overhaul of the U.S. health-care system.
For drugmakers, including Indianapolis-based Eli Lilly and Co., a meeting Tuesday with President Donald Trump was a dose of happy pills.
President Trump took Big Pharma to task on pricing but also promised to ease regulations and find ways to speed medicines to market, which triggered a surge in the sector’s share prices.
President Trump is fulfilling a promise he made shortly after his election to reduce federal regulations. In practice, the policy potentially requires months of study and public input for each regulation eliminated.
